Efficacy of Curettage Before Excision in Clearing Surgical Margins of Nonmelanoma Skin Cancer

Chiller, Katarina G.; Passaro, Douglas J.; McCalmont, Timothy H.; Vin-Christian, Kirsten

doi:10.1001/archderm.136.11.1327

Cited by 55 publications

(45 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…morpheaform and infiltrative) ( P < 0.01). The study further indicated that curettage before surgical excision of BCC decreased the incomplete excision rate by up to 24% ( P = 0.03) (71). A decrease in resection margin increases the recurrence rate.…”

Section: Surgerymentioning

confidence: 76%

An Overview on Basal Cell Carcinoma

Avcı¹

2011

Skin Cancer Overview

View full text Add to dashboard Cite

Section: Surgerymentioning

confidence: 76%

An Overview on Basal Cell Carcinoma

Avcı¹

2011

Skin Cancer Overview

View full text Add to dashboard Cite

“…For more invasive or highrisk tumors, histologic margin control is recommended. The excision margin for a primary, well-defined BCC or SCC with a diameter smaller than 2 cm in a low-risk location is 4 mm of normal-appearing skin [ [19] demonstrated a 26% improved cure rate for BCC that were curetted before excision compared with noncuretted excisions. Resected tissue is sent to the pathology laboratory for histologic examination, and the defect reconstructed.…”

Section: Excisional Surgerymentioning

confidence: 99%

Nonmelanoma skin cancer

Nguyen

2002

Curr. Treat. Options in Oncol.

111

View full text Add to dashboard Cite

Therapy for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) does not end with treatment of the initial lesion because almost 50% of patients with one nonmelanoma skin cancer (NMSC) develop another NMSC in the next 5 years. An integrated program of skin cancer awareness, sun protection, and prophylactic approaches is critical. The risk profile of the tumor influences which therapies and specialties will be involved. Most NMSCs may be treated with outpatient methods. Primary care physicians may treat low-risk tumors, but dermatologists specially trained in cutaneous oncology and a multidisciplinary team should manage high-risk lesions. Superficial BCC and SCC may be treated adequately with superficial modalities such as electrodesiccation and curettage (EDC) and cryotherapy. Topical 5-fluorouracil is effective for small in situ lesions. Invasive but low-risk lesions may be treated with EDC and cryotherapy provided that the tumor is limited to the papillary dermis, is not recurrent, and does not have high-risk features. High-risk tumors are best treated with excision and histologic examination or Mohs micrographic surgery (MMS). MMS is the therapeutic gold standard for all NMSCs in terms of cure rates, margin control, and tissue conservation. Because of its higher cost and specialized process, MMS is best reserved for specific indications.

show abstract

“…As incompletely excised SCCs recur if left untreated, they present a therapeutic dilemma (a potency for deep local invasion of the tumor and its spreading). A re-excision is recommended for all patients with incompletely excised SCC (1)(2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%